Sagitta Biotech is a company developping an innovative viral vector to develop efficient vaccines, oncolytic viruses and gene therapy vectors.
Our active virosome platform can deliver up to 17kb mRNA (6 genes), and elicit both humoral and cellular reponse.
Sagitta is developping its own pipeline of innovative multivalent vaccines (currently in preclinical phases) and oncolytic viruses, and is open to partnering and co-development.
In ancient Greece, Sagitta was regarded as the weapon that Hercules used to kill the eagle (Aquila) of Jove that perpetually gnawed Prometheus' liver.
Company Details
- Employees
- 4
- Founded
- 2019
- Address
- Avenue Pré Aily, 10, Liège,walloon Region 4031,belgium
- Industry
- Biotechnology
- Website
- http://www.sagittabiotech.com
- Keywords
- immunotherapy, cancer, oncolytic virus, checkpoint inhibitors, vaccines, multivalent vaccines, gene therapy.
- HQ
- Liège, Walloon Region
Sagitta Biotech Questions
Sagitta Biotech's website is http://www.sagittabiotech.com
Sagitta Biotech's LinkedIn profile is https://be.linkedin.com/company/sagitta-biotech
Sagitta Biotech has
4 employees.
View email and phone details for 4
employees at Sagitta Biotech.
Sagitta Biotech's industry is
Biotechnology
Sagitta Biotech's top competitors are
Amyl Therapeutics,
Neuvasq Biotechnologies,
Santero Therapeutics,
Allegro Biotech,
Hyloris Pharmaceuticals,
Epics Therapeutics,
Pdc*line Pharma,
Quantum Bioventure Studio,
Exo Biologics,
Quantoom Biosciences.
Sagitta Biotech's categories are Biotechnology
Sagitta Biotech's founding year is 2019
